10 ug: $40 Cat. No. U101 Click here to order
50 ug: $100 Cat. No. U102 Click here to order
250 ug: $345 Cat. No. U103 Click here to order
1 mg: $950 Cat. No. U104 Click here to order
10 mg: $4995 Cat. No. U105 Click here to order
Background: Tumor Necrosis Factor alpha (TNF-a or TNF-alpha) is a major inflammatory cytokine produced by macrophages/monocytes during acute inflammation and is responsible for a diverse range of signaling events within cells, leading to necrosis or apoptosis. Abnormality in TNF-alpha production in the absence of an infection is the major course for autoimmune diseases such as rheumatoid arthritis and psoriasis. TNF-a exerts many of its effects by binding, as a homo-trimer, to either a 55 kDa cell membrane receptor termed "TNFRI"/"TNF1" or a 75 kDa cell membrane receptor termed "TNFRII"/"TNFR2". Both of these receptors belong to the so-called TNF receptor superfamily.
Description: Recombinant human TNFRII-Fc Fusion Protein is produced in CHO cells as a dimeric, glycosylated, polypeptide chain consisting of the extracellular ligand-binding domain of the human tumor necrosis factor receptor II (p75) linked to the Fc region of human IgG1 (Ref. 1). The Fc domain contains the CH2 domain, the CH3 domain, and hinge region, but not the CH1 domain of IgG1. The mature secreted TNFRII-Fc fusion protein is a glycosylated and disulfide bond-linked dimer consisting of 934 amino acids with an apparent molecular weight of approximately 150 Kda. Under reducing conditions, the TNFRII-Fc fusion protein becomes a monomer with an apparent molecular weight of about 75 Kda.
Source: Produced from Chinese Hamster Ovarian (CHO) cells.
Formulation: 1 mg/mL in PBS, sterile filtered.
Stability: Stable for ~ 4 weeks at 4 degrees C. Long-term storage should be in small aliquots at -20 degrees C or -80 degrees C. Repeated thawing and freezing cycles should be avoided to minimize loss of activity.
Purity: Highly purified from Protein A Sepharose (> than 99.0% as determined by SDS-PAGE).
Biological Activity: Recombinant human TNFRII-Fc fusion protein is a potent blocker of TNF-alpha both in vitro and in vivo (Ref. 1 and 2). Its activity can be determined by its ability to neutralize TNF-alpha mediated apoptosis of either L929 or WEIH-13VAR cells (Ref. 3). IC50 of TNFRII-Fc is in the range of 5-15 ng/mL in the presence of 250 pg/mL of TNF-a. Ki is 2-6 ng/mL.
Usage: FOR RESEARCH USE ONLY. The product may not be used as a drug in human.
1.Mohler, K.M. et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol. 151, 1548-1561 (1993).
2.Wooley, P.H., Dutcher, J., Widmer, M.B. & Gillis, S. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol. 151, 6602-6607 (1993).
3.Khabar, K.S., Siddiqui, S. & Armstrong, J.A. WEHI-13VAR: a stable and sensitive variant of WEHI 164 clone 13 fibrosarcoma for tumor necrosis factor bioassay. Immunol Lett. 46, 107-110 (1995).
Additional Related Products:
sTNFRII-AP (Human) AP-Body (Cat. No. Q708) Click here for more info
TNF-alpha/sTNFR2-AP RLISA Kit (Cat. No. Q801) Click here for more info